This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound of formula I



I

wherein

R is H, A, A-CO-, Hal, -C≡C-H, -C≡C-A, or -C≡C-C(=O)-A,

R^1 is H, =O, Hal, A, OH, OA, A-COO-, Ph-$(CH_2)_n$-COO-, cycloalkyl-$(CH_2)_n$-COO-, A-CONH-, A-CONA-, Ph-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA, or $=CF_2$,

Ph is phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, or Hal,

R^2 is H, Hal, or A,

R^3 is a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, CN, $(CH_2)_nOH$, $(CH_2)_nHal$, NR^4R^5, =NH, =N-OH, =N-OA, and/or carbonyl oxygen (=O),

or $CONR^4R^5$,

R^4, R^5, independently of one another, are H or A,

R^4 and R^5 together may also be an alkylene chain having 3, 4 or 5 C atoms, which is optionally substituted by A, Hal, OA, and/or carbonyl oxygen (=CO),

A is unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally replaced by F or chlorine,

Hal is F, Cl, Br or I,

n is 0, 1, 2, 3 or 4,

or a pharmaceutically usable ~~derivative,~~ salt~~, solvate~~ or stereoisomer thereof, including mixtures thereof in all ratios.

2. (Previously Presented): A compound according to Claim 1, wherein R is Hal or -C≡C-H.

3. (Previously Presented): A compound according to Claim 1, wherein

R^3 is $CONR^4R^5$ or a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, =NH, and/or carbonyl oxygen (=O), and

$R^4$and R^5 independently of one another, are each H or A, or R^4 and R^5 together are an alkylene chain having 3, 4 or 5 C atoms.

4. (Currently Amended): A compound according to claim 1, wherein

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-imino-piperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, 4*H*-1,4-oxazin-4-yl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, or pyrazinyl, which in each case is optionally mono- or disubstituted by Hal and/or A, or is $CONR^4R^5$, and

R^4, R^5, independently of one another, are each H or A, or R^4 and R^5 together <u>are</u> ~~U~~ an alkylene chain having 3, 4 or 5 C atoms.

5. (Previously Presented): A compound according to claim 1, wherein

R^1 is H, =O, OH, OA, A-COO-, Ph-$(CH_2)_n$-COO-, or cycloalkyl-$(CH_2)_n$-COO-, and

Ph is unsubstituted phenyl.

6. (Previously Presented): A compound according to claim 1, wherein

R is Hal or -C≡C-H,

R^1 is H, =O, OH, OA, A-COO-, Ph-$(CH_2)_n$-COO-, or cycloalkyl-$(CH_2)_n$-COO-,

Ph is unsubstituted phenyl,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-imino-piperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, 4*H*-1,4-oxazin-4-yl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, or pyrazinyl, which in each case is optionally mono- or disubstituted by Hal and/or A, or is $CONR^4R^5$, and

R^4 and R^5 are each. independently of one another, H or A, or R^4 and R^5 together are an alkylene chain having 3, 4 or 5 C atoms.

7. (Previously Presented): A compound according to claim 1, wherein R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, or 4*H*-1,4-oxazin-4-yl, which in each case is optionally mono- or disubstituted by Hal and/or A.

8. (Previously Presented): A compound according to claim 1, wherein R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl,

4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, or 4*H*-1,4-oxazin-4-yl.

9. (Previously Presented): A compound according to claim 1, wherein

R is Hal or -C≡C-H,

R^1 is H, =O, OH, OA, A-COO-, Ph-$(CH_2)_n$-COO-, or cycloalkyl-$(CH_2)_n$-COO-,

Ph is unsubstituted phenyl,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, or 4*H*-1,4-oxazin-4-yl,

A is unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally replaced by F or chlorine,

Hal is F, Cl, Br or I, and

n is 0, 1, 2, 3 or 4.

10. (Currently Amended): A compound according to Claim 1, wherein said compound is:

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxopiperidin-1-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(2-oxopyrrolidinyl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(2-oxopyrrolidinyl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-trifluoromethyl-4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)-phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-chloro-4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)-phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(2-oxopyrrolidinyl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-4-oxopyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxopiperidinyl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-trifluoromethyl-4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-azabicyclo[2.2.2]-octan-3-on-2-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1,3-oxazinan-3-yl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}pyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(S)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-4-acetoxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-benzylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-4-benzoyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-4-*tert*-butylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-isobutylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-4-cyclohexylmethylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-4-cyclopentylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-cyclopropylmethylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-ethynylphenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-4-cyclobutylcarbonyloxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-pyrazolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(S)-4-hydroxypyrazolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-4-hydroxypyrazolidine-1,2-dicarboxamide,

or a pharmaceutically usable ~~derivative,~~ salt~~, solvate~~ or stereoisomers thereof, including mixtures thereof in all ratios.

11. (Withdrawn): A process for the preparation of a compound according to claim 1, said process comprising:

a) reacting a compound of formula II



II

with a chloroformate derivative to give an intermediate carbamate derivative, which is subsequently reacted with a compound of formula III-1



III-1

wherein if R^1 is OH, the OH group is optionally in protected form,

and subsequently optionally removing the OH-protecting group,

or

b) reacting a compound of the formula IV



IV,

with a chloroformate derivative to give an intermediate carbamate derivative, which is subsequently reacted with a compound of formula III-2



III-2

wherein if R^1 is H, the OH group is optionally in protected form,

and subsequently optionally removing the OH-protecting group,

and/or

(c) converting a base or acid of the formula I into one of its salts.

12. (Withdrawn): A method of inhibiting coagulation factor Xa comprising using a compound according to claim 1 as an inhibitor of coagulation factor Xa.

13. (Withdrawn): A method of inhibiting coagulation factor VIIa comprising using a compound according to claim 1 as an inhibitor of coagulation factor VIIa.

14. (Previously Presented): A pharmaceutical composition comprising at least one compound according to claim 1 and one or more excipients and/or adjuvants.

15. (Previously Presented): A pharmaceutical composition comprising at least one compound of the formula I according to claim 1 and at least one further medicament active ingredient.

16. (Withdrawn): A method of treating a patient suffering from thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to said patient an effective amount of a compound according to claim 1.

17 (Currently Amended): A kit comprising ~~of~~ separate packs of:

(a) an effective amount of a compound according to claim 1,

and

(b) an effective amount of a further medicament active ingredient.

18. (Withdrawn): A method of preparing a pharmaceutical composition for treating patient suffering from thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, said method comprising combining a compound according to claim 1 with at least one further medicament active ingredient.

19. (Withdrawn): A compound of formula III-1



III-1

wherein

R^1 is H, =O, Hal, A, OR^6, OA, A-COO-, Ph-$(CH_2)_n$-COO-, cycloalkyl-$(CH_2)_n$-COO-,

A-CONH-, A-CONA-, Ph-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA, or $=CF_2$,

Ph is phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, or Hal,

R^2 is H, Hal or A,

R^3 is a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, CN, $(CH_2)_nOH$, $(CH_2)_nHal$, NR^4R^5, =NH, =N-OH, =N-OA, and/or carbonyl oxygen (=O),

$CONR^4R^5$,

R^4 and R^5 are each, independently of one another, H or A, or R^4 and R^5 together are an alkylene chain having 3, 4 or 5 C atoms, which is optionally substituted by A, Hal, OA and/or carbonyl oxygen (=CO),

R^6 is an OH-protecting group,

A is unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally replaced by F or chlorine,

Hal is F, Cl, Br or I,

n is 0, 1, 2, 3 or 4,

or an isomer or salt thereof.

20. (Withdrawn): A compound according to Claim 19, wherein

R^1 is H, =O, OR^6, OA, A-COO-, Ph-$(CH_2)_n$-COO- or cycloalkyl-$(CH_2)_n$-COO-,

Ph is unsubstituted phenyl,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, or 4*H*-1,4-oxazin-4-yl,

R^6 is an OH-protecting group,

A is unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms

are each optionally replaced by F or chlorine,

Hal is F, Cl, Br or I,

n is 0, 1, 2, 3 or 4,

or an isomer or salt thereof.

21. (Withdrawn): A compound according to Claim 20, wherein

R^1 is H, =O, or OR^6,

R^2 is H, Hal, or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, or 4*H*-1,4-oxazin-4-yl,

R^6 is an alkylsilyl protecting group,

A is unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally replaced by F or chlorine,

Hal is F, Cl, Br or I,

n is 0, 1, 2, 3 or 4,

or an isomer or salt thereof.

22. (Withdrawn): A compound of formula III-2



III-2

wherein

R is H, A, A-CO-, Hal, -C≡C-H, -C≡C-A, or -C≡C-C(=O)-A,

R^1 is H, =O, Hal, A, OR^6, OA, A-COO-, Ph-$(CH_2)_n$-COO-, cycloalkyl-$(CH_2)_n$-COO-, A-CONH-, A-CONA-, Ph-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$,

CONHA, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA or $=CF_2$,

Ph is phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA or Hal,

R^6 is an OH-protecting group,

A is unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally replaced by F or chlorine,

Hal is F, Cl, Br or I,

n is 0, 1, 2, 3 or 4,

where, if R^1 is H, R is not Cl,

or an isomer or salt thereof.

23. (Withdrawn): A compound according to Claim 22, wherein

R is Hal or -C≡C-H,

R^1 is H, =O, OR^6, OA, A-COO-, Ph-$(CH_2)_n$-COO-, or cycloalkyl-$(CH_2)_n$-COO-,

Ph is phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, or Hal,

R^6 is an OH-protecting group,

A is unbranched, branched or cyclic alkyl having 1-10 C atoms, in which 1-7 H atoms are each optionally replaced by F or chlorine,

Hal is F, Cl, Br or I,

n is 0, 1, 2, 3 or 4,

where, if R^1 is H, R is not Cl,

or an isomer or salt thereof.

24. (Withdrawn): A compound according to Claim 22, wherein

R is Hal or -C≡C-H,

R^1 is H, =O, or OR^6,

R^6 is an alkylsilyl protecting group,

Hal is F, Cl, Br or I,

where, if R^1 is H, R is not Cl,

or an isomer or salt thereof.

25. (Withdrawn): A compound of formula VI



VI

wherein

R^1 is OH or OR^6,

R^6 is a silyl protecting group,

R^7 is *tert*-butyloxycarbonyl (BOC) or benzyloxycarbonyl (Z),

or an isomer thereof.

26. (Withdrawn): A process for the preparation of a compound of formula VI



VI

wherein

R^1 is OH or OR^6,

R^6 is a silyl protecting group,

R^7 is *tert*-butyloxycarbonyl (BOC) or benzyloxycarbonyl (Z),

or an isomer thereof, said process comprising:

reacting a compound of formula VII

$$R^7\text{-}NHNH_2 \qquad \text{VII},$$

wherein R^7 is *tert*-butyloxycarbonyl or benzyloxycarbonyl,

with silyl-protected 1,3-dibromopropan-2-ol, and optionally subsequently removing the protecting group.

27. (New): A method according to claim 16, wherein said patient is suffering from thromboses, myocardial infarction, or arteriosclerosis.

28. (New): A method according to claim 16, wherein said patient is suffering from inflammation.